NZ732978A - Il-17a-binding polypeptides - Google Patents
Il-17a-binding polypeptidesInfo
- Publication number
- NZ732978A NZ732978A NZ732978A NZ73297816A NZ732978A NZ 732978 A NZ732978 A NZ 732978A NZ 732978 A NZ732978 A NZ 732978A NZ 73297816 A NZ73297816 A NZ 73297816A NZ 732978 A NZ732978 A NZ 732978A
- Authority
- NZ
- New Zealand
- Prior art keywords
- binding polypeptides
- interleukin
- binding polypeptide
- binding
- x26lx28x29
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000013691 Interleukin-17 Human genes 0.000 abstract 4
- 108050003558 Interleukin-17 Proteins 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Wood Science & Technology (AREA)
- Obesity (AREA)
- Neurology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15150786 | 2015-01-12 | ||
| PCT/EP2016/050456 WO2016113246A1 (en) | 2015-01-12 | 2016-01-12 | Il-17a-binding polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ732978A true NZ732978A (en) | 2022-01-28 |
Family
ID=52339024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ732978A NZ732978A (en) | 2015-01-12 | 2016-01-12 | Il-17a-binding polypeptides |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10934335B2 (pl) |
| EP (2) | EP3245224B1 (pl) |
| JP (3) | JP6943764B2 (pl) |
| KR (2) | KR20240110106A (pl) |
| CN (1) | CN108064235A (pl) |
| AU (1) | AU2016208161B2 (pl) |
| BR (1) | BR112017014559A2 (pl) |
| CA (1) | CA2972683A1 (pl) |
| DK (1) | DK3245224T3 (pl) |
| ES (1) | ES2822431T3 (pl) |
| HU (1) | HUE052121T2 (pl) |
| IL (1) | IL253004B (pl) |
| MX (1) | MX2017008660A (pl) |
| MY (1) | MY188784A (pl) |
| NZ (1) | NZ732978A (pl) |
| PL (1) | PL3245224T3 (pl) |
| PT (1) | PT3245224T (pl) |
| RU (1) | RU2749712C2 (pl) |
| WO (1) | WO2016113246A1 (pl) |
| ZA (1) | ZA201704366B (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY37651A (es) * | 2017-03-31 | 2018-10-31 | Swedish Orphan Biovitrum Ab Publ | Polipéptido de unión al il-1r-i |
| CN108949789A (zh) * | 2018-06-26 | 2018-12-07 | 山东兴瑞生物科技有限公司 | 抗gcc的核酸、其制备方法、具有该核酸的免疫细胞及其应用 |
| US20220389066A1 (en) * | 2019-11-05 | 2022-12-08 | Affibody Ab | Polypeptides |
| CN111856029B (zh) * | 2020-06-19 | 2023-09-26 | 北华大学 | Il-17a蛋白在膀胱癌中的应用 |
| KR20240139058A (ko) * | 2022-02-08 | 2024-09-20 | 애피바디 에이비 | 흉선 기질 림포포이에틴에 결합하는 단백질 z 변이체 및 이의 의학적 용도 |
| WO2023196913A2 (en) * | 2022-04-07 | 2023-10-12 | Acelyrin, Inc. | Methods of treating ankylosing spondylitis |
| WO2023196916A1 (en) * | 2022-04-07 | 2023-10-12 | Acelyrin, Inc. | Methods of treating of hidradenitis suppurativa |
| CN116466095B (zh) * | 2023-06-15 | 2023-09-01 | 朗肽生物制药股份有限公司 | 一种多肽及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0524788D0 (en) * | 2005-12-05 | 2006-01-11 | Affibody Ab | Polypeptides |
| RS57255B1 (sr) | 2005-12-13 | 2018-08-31 | Lilly Co Eli | Anti-il-17 antitela |
| US8937153B2 (en) | 2007-07-31 | 2015-01-20 | Affibody Ab | Compositions, methods and uses |
| ATE527353T1 (de) | 2007-12-19 | 2011-10-15 | Affibody Ab | Pdgf-bindendes polypeptid aus protein a |
| MX2011009362A (es) | 2009-03-05 | 2011-09-26 | Abbott Lab | Proteinas de union a il-17. |
| EP2470556B1 (en) | 2009-08-27 | 2018-05-30 | Covagen AG | Il-17 binding compounds and medical uses thereof |
| US9175067B2 (en) * | 2010-03-08 | 2015-11-03 | Ge Healthcare Bio-Sciences Ab | Immunoglobulin G Fc region binding polypeptide |
| ES2676403T3 (es) | 2010-07-09 | 2018-07-19 | Affibody Ab | Polipéptidos |
| WO2012125680A1 (en) | 2011-03-16 | 2012-09-20 | Novartis Ag | Methods of treating vasculitis using an il-17 binding molecule |
| EP2597102A1 (en) * | 2011-11-25 | 2013-05-29 | Covagen AG | A novel fusion protein comprising an antibody light chain and a polypeptide binding to IL-17 |
| EP2817329B1 (en) * | 2012-02-20 | 2019-01-02 | Swedish Orphan Biovitrum AB (Publ) | Polypeptides binding to human complement c5 |
| EP2711016A1 (en) * | 2012-09-21 | 2014-03-26 | Covagen AG | Novel IL-17A binding molecules and medical uses thereof |
| KR102123457B1 (ko) | 2012-09-25 | 2020-06-16 | 애피바디 에이비 | 알부민 결합 폴리펩타이드 |
| CN104854127B (zh) | 2012-10-25 | 2020-12-25 | 阿菲博迪公司 | 白蛋白结合多肽 |
| EP2946214A1 (en) * | 2013-01-21 | 2015-11-25 | AbbVie Inc. | Anti-tnf and anti-il17 combination therapy biomarkers for inflammatory disease |
| MY171407A (en) * | 2013-03-15 | 2019-10-11 | Affibody Ab | New polypeptides |
| WO2015091957A1 (en) | 2013-12-20 | 2015-06-25 | Affibody Ab | Engineered albumin binding polypeptide |
-
2016
- 2016-01-12 DK DK16700424.1T patent/DK3245224T3/da active
- 2016-01-12 HU HUE16700424A patent/HUE052121T2/hu unknown
- 2016-01-12 RU RU2017127012A patent/RU2749712C2/ru active
- 2016-01-12 CA CA2972683A patent/CA2972683A1/en active Pending
- 2016-01-12 ES ES16700424T patent/ES2822431T3/es active Active
- 2016-01-12 KR KR1020247022438A patent/KR20240110106A/ko active Search and Examination
- 2016-01-12 WO PCT/EP2016/050456 patent/WO2016113246A1/en active Application Filing
- 2016-01-12 AU AU2016208161A patent/AU2016208161B2/en active Active
- 2016-01-12 NZ NZ732978A patent/NZ732978A/en unknown
- 2016-01-12 EP EP16700424.1A patent/EP3245224B1/en active Active
- 2016-01-12 CN CN201680011379.3A patent/CN108064235A/zh active Pending
- 2016-01-12 JP JP2017535976A patent/JP6943764B2/ja active Active
- 2016-01-12 PL PL16700424T patent/PL3245224T3/pl unknown
- 2016-01-12 EP EP20180610.6A patent/EP3738976A1/en active Pending
- 2016-01-12 KR KR1020177021726A patent/KR102683288B1/ko active Application Filing
- 2016-01-12 US US15/538,890 patent/US10934335B2/en active Active
- 2016-01-12 PT PT167004241T patent/PT3245224T/pt unknown
- 2016-01-12 MY MYPI2017702236A patent/MY188784A/en unknown
- 2016-01-12 BR BR112017014559-6A patent/BR112017014559A2/pt active Search and Examination
- 2016-01-12 MX MX2017008660A patent/MX2017008660A/es unknown
-
2017
- 2017-06-19 IL IL253004A patent/IL253004B/en active IP Right Grant
- 2017-06-27 ZA ZA2017/04366A patent/ZA201704366B/en unknown
-
2020
- 2020-12-17 JP JP2020209139A patent/JP7208963B2/ja active Active
-
2021
- 2021-02-01 US US17/163,961 patent/US20210253659A1/en active Pending
-
2023
- 2023-01-06 JP JP2023001177A patent/JP7456024B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ732978A (en) | Il-17a-binding polypeptides | |
| MX2018005399A (es) | Nuevo polipeptido con afinidad por pd-l1. | |
| EP3957723A3 (en) | Engineered ligase variants | |
| PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
| ZA202100676B (en) | Anti-tigit antibody and uses thereof | |
| MY196646A (en) | Agonistic Antibodies Specifically Binding Human CD40 And Methods of use | |
| MX2018005550A (es) | Anticuerpos que se unen especificamente a tim-3 y sus usos. | |
| MX2018011503A (es) | Proteinas de union y metodos de uso de las mismas. | |
| MY198059A (en) | Anti-ox40 antibodies and their uses | |
| SG10201909716RA (en) | Modified j-chain | |
| MX2021008318A (es) | Nuevos polipeptidos de union especifica y usos de los mismos. | |
| SG10201808523RA (en) | Il-22 polypeptides and il-22 fc fusion proteins and methods of use | |
| SA519402159B1 (ar) | بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها | |
| MX2015012872A (es) | Anticuerpos anti-tau y metodos de uso. | |
| MX2017003211A (es) | Anticuerpos anti-met y composiciones. | |
| PH12015501854A1 (en) | Factor ix polypeptide formulations | |
| MY188405A (en) | Anti-cd154 antibodies and methods of using them | |
| WO2015031778A3 (en) | Compositions and methods for the treatment or prevention of tuberculosis | |
| MX2017012596A (es) | Una composicion farmaceutica y el uso de la misma. | |
| PH12016500371B1 (en) | Stable polypeptides binding to human complement c5 | |
| PH12019502694A1 (en) | Anti-trkb antibodies | |
| SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| MX2018013556A (es) | Polipeptidos variantes con rendimiento mejorado y uso de los mismos. | |
| MX2018009218A (es) | Anticuerpos de cgrp y sus usos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JAN 2024 BY AWA SWEDEN AB Effective date: 20221217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JAN 2025 BY AWA SWEDEN AB Effective date: 20231215 |